This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...